Converge Bio raises $25 million for AI drug discovery, backed by Meta and OpenAI executives

When OpenAI executives put their own money into a biotech startup, that's a signal hard to ignore. Converge Bio, a young company working on AI-driven drug discovery, has just closed a $25 million Series A round and pulled together an impressive coalition of Big Tech investors.

Bessemer Venture Partners led the round. It is one of Silicon Valley's oldest and most respected venture firms, with a portfolio that includes Pinterest, Shopify, and Twilio. The angel investor lineup is just as notable: it includes executives from Meta, OpenAI, and Wiz, the Israeli cybersecurity startup recently valued at $12 billion.

This mix of investors reflects a fundamental shift in how the tech community sees biopharma. Just five years ago, tech investors considered drug development too slow, too heavily regulated, and too capital-intensive. Today, generative AI is changing the rules.

Converge Bio works in AI drug discovery, which uses machine learning to speed up the search for molecules that could become future drugs. The traditional process takes years and costs billions of dollars. Algorithms can sift through millions of potential compounds, predict their properties, and weed out unpromising candidates early on.

The market for AI in pharma is booming. According to analysts, it could reach $4 billion by 2030. Major players such as Insilico Medicine, Recursion Pharmaceuticals, and Exscientia have already moved AI-designed drugs into clinical trials. Converge Bio enters the race with serious financial resources, but on a highly competitive field.

The involvement of OpenAI executives is especially symbolic. The company that built GPT-4 has unique expertise in large language models. Their interest in biotech may signal that the next AI breakthrough will come not in text or image generation, but in molecular modeling.

For Russian observers, the deal highlights a widening funding gap for research-intensive AI startups. While domestic biotech companies compete for grants worth tens of millions of rubles, their American rivals raise comparable sums in dollars, along with access to top-tier GPU clusters and clinical trial data.

The $25 million is fuel for a race whose outcome will decide who develops the next generation of drugs. Converge Bio has gained not only money but also access to the tech elite's network. Now it's up to the scientists and the algorithms.

*Meta is designated an extremist organization and banned in Russia.